Fifth Third Wealth Advisors LLC Raises Position in Humana Inc. $HUM

Fifth Third Wealth Advisors LLC lifted its stake in shares of Humana Inc. (NYSE:HUM) by 8.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,337 shares of the insurance provider’s stock after purchasing an additional 100 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Humana were worth $327,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HUM. Vanguard Group Inc. increased its stake in shares of Humana by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after purchasing an additional 1,143,662 shares during the last quarter. AQR Capital Management LLC grew its stake in Humana by 3,257.5% in the 1st quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider’s stock valued at $307,624,000 after buying an additional 1,127,973 shares in the last quarter. Nuveen LLC purchased a new position in Humana in the 1st quarter valued at approximately $171,220,000. Dodge & Cox grew its stake in Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after buying an additional 557,175 shares in the last quarter. Finally, Pzena Investment Management LLC grew its stake in Humana by 6.1% in the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock valued at $1,013,133,000 after buying an additional 219,541 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $270.84 on Tuesday. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $315.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The company has a market capitalization of $32.57 billion, a P/E ratio of 20.79, a P/E/G ratio of 1.64 and a beta of 0.42. The company has a fifty day moving average of $279.92 and a 200-day moving average of $258.09.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the firm posted $6.96 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s payout ratio is currently 27.17%.

Wall Street Analyst Weigh In

HUM has been the subject of a number of recent research reports. Wells Fargo & Company lifted their price objective on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a research note on Tuesday, October 7th. Wolfe Research lifted their price objective on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research note on Monday, October 6th. Barclays reduced their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research note on Friday, October 3rd. Royal Bank Of Canada lifted their price objective on shares of Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a research note on Thursday, August 21st. Finally, Robert W. Baird reduced their price objective on shares of Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research note on Friday, July 25th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $298.83.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.